Zivo Bioscience Files 8-K on Equity Sale

TL;DR

Zivo Bioscience sold unregistered equity, raising capital.

AI Summary

On October 17, 2024, Zivo Bioscience, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The company issued warrants to purchase shares of its common stock, with the earliest event reported on October 17, 2024. Specific details regarding the number of shares, exercise price, and total proceeds from the sale were not fully disclosed in the provided text.

Why It Matters

This filing indicates Zivo Bioscience is raising capital through the sale of equity, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — Unregistered equity sales can sometimes signal financial distress or dilution concerns for existing shareholders.

Key Players & Entities

• Zivo Bioscience, Inc. (company) — Registrant
• October 17, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of Incorporation
• 21 East Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304 (address) — Principal Executive Office Address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to
• $0 — f the Company's common stock, par value $0.001, at prices per share between $8.34
• $8.34 — lue $0.001, at prices per share between $8.34 and $16.31, and at an average price of
• $16 — , at prices per share between $8.34 and $16.31, and at an average price of $10.44 p
• $10.44 — and $16.31, and at an average price of $10.44 per share to a number of accredited inv
• $15 — ted parties at prices between $8.34 and $15.96, and an average of $9.68 per share.
• $9.68 — een $8.34 and $15.96, and an average of $9.68 per share. No solicitation was made and

Filing Documents

• zivo_8k.htm (8-K) — 24KB
• 0001654954-24-013107.txt ( ) — 156KB
• zivo-20241017.xsd (EX-101.SCH) — 6KB
• zivo-20241017_lab.xml (EX-101.LAB) — 15KB
• zivo-20241017_cal.xml (EX-101.CAL) — 1KB
• zivo-20241017_pre.xml (EX-101.PRE) — 11KB
• zivo-20241017_def.xml (EX-101.DEF) — 4KB
• zivo_8k_htm.xml (XML) — 5KB

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. Between August 22, 2024 and October 17, 2024, Zivo Bioscience, Inc. (the "Company") sold 169,022 shares of the Company's common stock, par value $0.001, at prices per share between $8.34 and $16.31, and at an average price of $10.44 per share to a number of accredited investors. Of the total shares sold, 52,802 were sold to related parties at prices between $8.34 and $15.96, and an average of $9.68 per share. No solicitation was made and no underwriting discounts were given or paid in connection with this transaction. The common stock was not registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state, and was offered and sold in reliance on the exemption from registration afforded by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act and corresponding provisions of state securities laws, which exempts transactions by an issuer not involving any public offering. As of October 17, 2024, the Company has 3,535,134 common stock shares outstanding. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZIVO BIOSCIENCE, INC. By: /s/ Keith Marchiando Keith Marchiando Chief Financial Officer Date: October 18, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR